Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
Cagri Reta (cagrilintide with retatrutide)
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
Cagri Reta is a catalogue name for a proposed combination of cagrilintide, a long-acting amylin analogue, and retatrutide, an investigational GIP/GLP-1/glucagon receptor agonist.
The exact combination and the separate 40mg plus 4mg pen presentation are not established medicines. Evidence about either component cannot simply be added together to prove the combination's safety or effectiveness.
Intended / recognised uses
Authorised / recognised uses
- There are no authorised UK medical uses for this combination.
Reported / investigational uses
- The components are discussed in metabolic and appetite research, but reliable clinical evidence for this exact combined product is not established.
- Theoretical or online claims are not a substitute for controlled clinical evidence.
How it works
Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors. Cagrilintide is designed to mimic amylin signalling related to satiety.
How these actions interact in this exact combination, including additive adverse effects, has not been adequately characterised.
Potential benefits / effects
- No reliable clinical benefit has been established for the exact cagrilintide–retatrutide combination shown here.
- Results from studies of retatrutide alone or cagrilintide with semaglutide cannot validate this product or predict an individual's outcome.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- Short- and long-term safety are unknown for the exact combination.
- Potential additive concerns include nausea, vomiting, diarrhoea or constipation, dehydration, hypoglycaemia with diabetes medicines, pancreatitis, gallbladder effects, altered gastric emptying and heart-rate changes.
- Unregulated supply adds risks involving identity, potency, contamination, sterility and storage.
Possible side effects
Frequency not established
- There is no reliable common-side-effect frequency for this exact product.
- Gastrointestinal symptoms and reduced appetite are plausible from component trial experience, but extrapolation is uncertain.
Serious or urgent concerns
- Severe abdominal pain, persistent vomiting, severe dehydration, significant hypoglycaemia or allergic reaction requires urgent assessment.
- Unknown adverse effects remain possible because the combination has not been adequately studied.
Who should not use it / precautions
- It should not be used in people outside an appropriately authorised research study.
- Pregnancy, breastfeeding, childhood, diabetes treated with glucose-lowering drugs, previous pancreatitis, severe gastrointestinal disease, kidney or liver disease and gallbladder disease increase concern.
- Absence of a listed contraindication does not mean the product is suitable.
Interactions
- No reliable interaction studies exist for the exact combination.
- Insulin or sulfonylureas could increase hypoglycaemia risk, and slowed gastric emptying could affect oral medicines.
- Combining it with GLP-1, GIP, amylin or other weight-management medicines may compound effects and risks.
Regulatory / legal status
- Neither retatrutide nor this cagrilintide–retatrutide combination has a UK marketing authorisation.
- The HELIX dual-pen presentation should not be described as approved, licensed or clinically validated.
Monitoring / professional supervision
- There is no validated monitoring protocol for self-directed use of this product.
- A legitimate clinical study would require eligibility screening, authenticated study medicine, adverse-event reporting and protocol-led metabolic and safety monitoring.
- This page intentionally gives no dosing instructions.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- MHRA — Retatrutide is not authorised in the UK
- PubMed — Retatrutide phase 2 obesity trial
- ClinicalTrials.gov — Cagrilintide/semaglutide study (not this combination)
- MHRA — GLP-1 medicine safety information
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.